Top

BMC Cancer

Published in:

Open Access 01-12-2018 | Research article

A molecular and staging model predicts survival in patients with resected non-small cell lung cancer

Authors: Lei Liu, Minxin Shi, Zhiwei Wang, Haimin Lu, Chang Li, Yu Tao, Xiaoyan Chen, Jun Zhao

Published in: BMC Cancer | Issue 1/2018

Abstract

Background

The current TNM staging system is far from perfect in predicting the survival of individual non-small cell lung cancer (NSCLC) patients. In this study, we aim to combine clinical variables and molecular biomarkers to develop a prognostic model for patients with NSCLC.

Methods

Candidate molecular biomarkers were extracted from the Gene Expression Omnibus (GEO), and Cox regression analysis was performed to determine significant prognostic factors. The survival prediction model was constructed based on multivariable Cox regression analysis in a cohort of 152 NSCLC patients. The predictive performance of the model was assessed by the Area under the Receiver Operating Characteristic Curve (AUC) and Kaplan–Meier survival analysis.

Results

The survival prediction model consisting of two genes (TPX2 and MMP12) and two clinicopathological factors (tumor stage and grade) was developed. The patients could be divided into either high-risk group or low-risk group. Both disease-free survival and overall survival were significantly different among the diverse groups (P < 0.05). The AUC of the prognostic model was higher than that of the TNM staging system for predicting survival.

Conclusions

We developed a novel prognostic model which can accurately predict outcomes for patients with NSCLC after surgery.

Available only for authorised users

Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J, Jemal A. Global cancer statistics, 2012. CA Cancer J Clin. 2015;65(2):87–108. https://doi.org/10.3322/caac.21262.CrossRef

Wang S, Sun T, Sun H, Li X, Li J, Zheng X, et al. Survival improvement in patients with non-small cell lung cancer between 1983 and 2012: analysis of the surveillance, epidemiology, and end results database. Tumour Biol. 2017;39(5). https://doi.org/10.1177/1010428317691677.CrossRef

Chansky K, Sculier JP, Crowley JJ, Giroux D, Van Meerbeeck J, Goldstraw P. The International Association for the Study of Lung Cancer staging project: prognostic factors and pathologic TNM stage in surgically managed non-small cell lung cancer. J Thorac Oncol 2009;4(7):792–801. doi:https://doi.org/10.1097/JTO.0b013e3181a7716e.CrossRef

Sun F, Ma K, Yang X, Li M, Shi Y, Zhan C, et al. A nomogram to predict prognosis after surgery in early stage non-small cell lung cancer in elderly patients. Int J Surg. 2017;42:11–6. https://doi.org/10.1016/j.ijsu.2017.04.024.CrossRefPubMed

Ong CA, Shapiro J, Nason KS, Davison JM, Liu X, Ross-Innes C, et al. Three-gene immunohistochemical panel adds to clinical staging algorithms to predict prognosis for patients with esophageal adenocarcinoma. J Clin Oncol. 2013;31(12):1576–82. https://doi.org/10.1200/JCO.2012.45.9636.CrossRefPubMedPubMedCentral

Wang X, Liu Y, Niu Z, Fu R, Jia Y, Zhang L, et al. Prognostic value of a 25-gene assay in patients with gastric cancer after curative resection. Sci Rep. 2017;7(1):7515. https://doi.org/10.1038/s41598-017-07604-y.CrossRefPubMedPubMedCentral

Kim HS, Umbricht CB, Illei PB, Cimino-Mathews A, Cho S, Chowdhury N, et al. Optimizing the use of gene expression profiling in early-stage breast Cancer. J Clin Oncol. 2016;34(36):4390–7. https://doi.org/10.1200/JCO.2016.67.7195.CrossRefPubMedPubMedCentral

Sho S, Court CM, Winograd P, Russell MM, Tomlinson JS. A prognostic mutation panel for predicting cancer recurrence in stages II and III colorectal cancer. J Surg Oncol. 2017. https://doi.org/10.1002/jso.24781.CrossRef

Cao HH, Zhang SY, Shen JH, Wu ZY, Wu JY, Wang SH, et al. A three-protein signature and clinical outcome in esophageal squamous cell carcinoma. Oncotarget. 2015;6(7):5435–48. https://doi.org/10.18632/oncotarget.3102.CrossRefPubMed

10.

Chang W, Gao X, Han Y, Du Y, Liu Q, Wang L, et al. Gene expression profiling-derived immunohistochemistry signature with high prognostic value in colorectal carcinoma. Gut. 2014;63(9):1457–67. https://doi.org/10.1136/gutjnl-2013-305475.CrossRefPubMed

11.

Li L, Wei Y, To C, Zhu CQ, Tong J, Pham NA, et al. Integrated omic analysis of lung cancer reveals metabolism proteome signatures with prognostic impact. Nat Commun. 2014;5:5469. https://doi.org/10.1038/ncomms6469.CrossRefPubMed

12.

Guo NL, Dowlati A, Raese RA, Dong C, Chen G, Beer DG, et al. A predictive 7-gene assay and prognostic protein biomarkers for non-small cell lung Cancer. EBioMedicine. 2018;32:102–10. https://doi.org/10.1016/j.ebiom.2018.05.025.CrossRefPubMedPubMedCentral

13.

Camp RL, Dolled-Filhart M, Rimm DL. X-tile: a new bio-informatics tool for biomarker assessment and outcome-based cut-point optimization. Clin Cancer Res. 2004;10(21):7252–9. https://doi.org/10.1158/1078-0432.CCR-04-0713.CrossRef

14.

Schneider MA, Christopoulos P, Muley T, Warth A, Klingmueller U, Thomas M, et al. AURKA, DLGAP5, TPX2, KIF11 and CKAP5: five specific mitosis-associated genes correlate with poor prognosis for non-small cell lung cancer patients. Int J Oncol. 2017;50(2):365–72. https://doi.org/10.3892/ijo.2017.3834.CrossRefPubMedPubMedCentral

15.

Gentles AJ, Bratman SV, Lee LJ, Harris JP, Feng W, Nair RV, et al. Integrating tumor and stromal gene expression signatures with clinical indices for survival stratification of early-stage non-small cell lung Cancer. J Natl Cancer Inst. 2015;107(10). https://doi.org/10.1093/jnci/djv211.CrossRef

16.

Liang W, Zhang L, Jiang G, Wang Q, Liu L, Liu D, et al. Development and validation of a nomogram for predicting survival in patients with resected non-small-cell lung cancer. J Clin Oncol. 2015;33(8):861–9. https://doi.org/10.1200/JCO.2014.56.6661.CrossRefPubMed

17.

Mecklenburg I, Sienel W, Schmid S, Passlick B, Kufer P. A threshold of systemic MAGE-A gene expression predicting survival in resected non-small cell lung Cancer. Clin Cancer Res. 2017;23(5):1213–9. https://doi.org/10.1158/1078-0432.CCR-16-0557.CrossRefPubMed

18.

Wu J, Zhou L, Huang L, Gu J, Li S, Liu B, et al. Nomogram integrating gene expression signatures with clinicopathological features to predict survival in operable NSCLC: a pooled analysis of 2164 patients. J Exp Clin Cancer Res. 2017;36(1):4. https://doi.org/10.1186/s13046-016-0477-x.CrossRefPubMedPubMedCentral

19.

Zeng Q, Xue N, Dai D, Xing S, He X, Li S, et al. A nomogram based on inflammatory factors C-reactive protein and fibrinogen to predict the prognostic value in patients with resected non-small cell lung Cancer. J Cancer. 2017;8(5):744–53. https://doi.org/10.7150/jca.17423.CrossRefPubMedPubMedCentral

20.

Ohbayashi H. Matrix metalloproteinases in lung diseases. Curr Protein Pept Sci. 2002;3(4):409–21.CrossRef

21.

Xu J, E C YY, Ren S, Wang G, Jin H. Matrix metalloproteinase expression and molecular interaction network analysis in gastric cancer. Oncol Lett. 2016;12(4):2403–8. https://doi.org/10.3892/ol.2016.5013.CrossRefPubMedPubMedCentral

22.

Klupp F, Neumann L, Kahlert C, Diers J, Halama N, Franz C, et al. Serum MMP7, MMP10 and MMP12 level as negative prognostic markers in colon cancer patients. BMC Cancer. 2016;16:494. https://doi.org/10.1186/s12885-016-2515-7.CrossRefPubMedPubMedCentral

23.

Hass HG, Vogel U, Scheurlen M, Jobst J. Gene-expression analysis identifies specific patterns of dysregulated molecular pathways and genetic subgroups of human hepatocellular carcinoma. Anticancer Res. 2016;36(10):5087–95. https://doi.org/10.21873/anticanres.11078.CrossRefPubMed

24.

Ng KT, Qi X, Kong KL, Cheung BY, Lo CM, Poon RT, et al. Overexpression of matrix metalloproteinase-12 (MMP-12) correlates with poor prognosis of hepatocellular carcinoma. Eur J Cancer. 2011;47(15):2299–305. https://doi.org/10.1016/j.ejca.2011.05.032.CrossRef

25.

Lv FZ, Wang JL, Wu Y, Chen HF, Shen XY. Knockdown of MMP12 inhibits the growth and invasion of lung adenocarcinoma cells. Int J Immunopathol Pharmacol. 2015;28(1):77–84. https://doi.org/10.1177/0394632015572557.CrossRefPubMed

26.

Glaser ZA, Love HD, Guo S, Gellert L, Chang SS, Herrell SD, et al. TPX2 as a prognostic indicator and potential therapeutic target in clear cell renal cell carcinoma. Urol Oncol. 2017;35(5):286–93. https://doi.org/10.1016/j.urolonc.2016.12.012.CrossRefPubMed

27.

Caceres-Gorriti KY, Carmona E, Barres V, Rahimi K, Letourneau IJ, Tonin PN, et al. RAN nucleo-cytoplasmic transport and mitotic spindle assembly partners XPO7 and TPX2 are new prognostic biomarkers in serous epithelial ovarian cancer. PLoS One. 2014;9(3):e91000. https://doi.org/10.1371/journal.pone.0091000.CrossRefPubMedPubMedCentral

28.

Hsu PK, Chen HY, Yeh YC, Yen CC, Wu YC, Hsu CP, et al. TPX2 expression is associated with cell proliferation and patient outcome in esophageal squamous cell carcinoma. J Gastroenterol. 2014;49(8):1231–40. https://doi.org/10.1007/s00535-013-0870-6.CrossRefPubMed

29.

Huang Y, Guo W, Kan H. TPX2 is a prognostic marker and contributes to growth and metastasis of human hepatocellular carcinoma. Int J Mol Sci. 2014;15(10):18148–61. https://doi.org/10.3390/ijms151018148.CrossRefPubMedPubMedCentral

30.

Tomii C, Inokuchi M, Takagi Y, Ishikawa T, Otsuki S, Uetake H, et al. TPX2 expression is associated with poor survival in gastric cancer. World J Surg Oncol. 2017;15(1):14. https://doi.org/10.1186/s12957-016-1095-y.CrossRefPubMedPubMedCentral

31.

Wei P, Zhang N, Xu Y, Li X, Shi D, Wang Y, et al. TPX2 is a novel prognostic marker for the growth and metastasis of colon cancer. J Transl Med. 2013;11:313. https://doi.org/10.1186/1479-5876-11-313.CrossRefPubMedPubMedCentral

32.

Chang H, Wang J, Tian Y, Xu J, Gou X, Cheng J. The TPX2 gene is a promising diagnostic and therapeutic target for cervical cancer. Oncol Rep. 2012;27(5):1353–9. https://doi.org/10.3892/or.2012.1668.CrossRefPubMed

33.

Mencoboni M, Filiberti RA, Taveggia P, Bruzzone A, Garuti A, Del Corso L, et al. Outcome of EGFR inhibitors treatment in advanced NSCLC patients, not enrolled in clinical trials. Neoplasma. 2017;64(2):253–61. https://doi.org/10.4149/neo_2017_212.CrossRefPubMed

Title: A molecular and staging model predicts survival in patients with resected non-small cell lung cancer
Authors: Lei Liu
Minxin Shi
Zhiwei Wang
Haimin Lu
Chang Li
Yu Tao
Xiaoyan Chen
Jun Zhao
Publication date: 01-12-2018
Publisher: BioMed Central
Published in: BMC Cancer / Issue 1/2018
Electronic ISSN: 1471-2407
DOI: https://doi.org/10.1186/s12885-018-4881-9

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Abstract

Background

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 1/2018

Neo-adjuvant treatment of adenocarcinoma and squamous cell carcinoma of the cervix results in significantly different pathological complete response rates

Oral mucositis associated with anti-EGFR therapy in colorectal cancer: single institutional retrospective cohort study

MCM family in HCC: MCM6 indicates adverse tumor features and poor outcomes and promotes S/G2 cell cycle progression

‘DURVIT’: a phase-I trial of single low-dose durvalumab (Medi4736) IntraTumourally injected in cervical cancer: safety, toxicity and effect on the primary tumour- and lymph node microenvironment

Single-stranded DNA binding protein 2 expression is associated with patient survival in hepatocellular carcinoma

Patients’ quality of life during active cancer treatment: a qualitative study

Keynote webinar | Spotlight on antibody–drug conjugates in cancer